These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30001427)

  • 21. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study.
    Bellentani S; Pozzato G; Saccoccio G; Crovatto M; Crocè LS; Mazzoran L; Masutti F; Cristianini G; Tiribelli C
    Gut; 1999 Jun; 44(6):874-80. PubMed ID: 10323892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
    Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The burden of hepatitis C in England.
    Sweeting MJ; De Angelis D; Brant LJ; Harris HE; Mann AG; Ramsay ME
    J Viral Hepat; 2007 Aug; 14(8):570-6. PubMed ID: 17650291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncologic Implications of Chronic Hepatitis C Virus Infection.
    Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
    J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
    Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
    BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
    Nousbaum JB; Pol S; Nalpas B; Landais P; Berthelot P; Bréchot C
    Ann Intern Med; 1995 Feb; 122(3):161-8. PubMed ID: 7810932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current status and clinical course of hepatitis C virus in Korea].
    Kwon JH; Bae SH
    Korean J Gastroenterol; 2008 Jun; 51(6):360-7. PubMed ID: 18604137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic performances of hepatitis C virus-NS4 antigen in patients with different liver pathologies.
    Attallah AM; Omran MM; Nasif WA; Ghaly MF; El-Shanshoury Ael-R; Abdalla MS; Sharada HM; Farid K; El-Shony W; Moussa el-SM; El-Domany EB; Nour E; Eldosoky I
    Arch Med Res; 2012 Oct; 43(7):555-62. PubMed ID: 23085447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
    Perz JF; Armstrong GL; Farrington LA; Hutin YJ; Bell BP
    J Hepatol; 2006 Oct; 45(4):529-38. PubMed ID: 16879891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.
    Sibley A; Han KH; Abourached A; Lesmana LA; Makara M; Jafri W; Salupere R; Assiri AM; Goldis A; Abaalkhail F; Abbas Z; Abdou A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alavian SM; Alashgar HI; Alawadhi S; Al-Dabal L; Aldins P; Alfaleh FZ; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Alzaabi M; Andrea N; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Blach S; Chaudhry A; Choi MS; Diab T; Djauzi S; El Hassan ES; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Gheorghe L; Gottfredsson M; Gregorcic S; Gunter J; Hajarizadeh B; Hamid S; Hasan I; Hashim A; Horvath G; Hunyady B; Husni R; Jeruma A; Jonasson JG; Karlsdottir B; Kim DY; Kim YS; Koutoubi Z; Liakina V; Lim YS; Löve A; Maimets M; Malekzadeh R; Matičič M; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Nugrahini N; Olafsson S; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Sharara AI; Siddiq M; Siddiqui AM; Sigmundsdottir G; Sigurdardottir B; Speiciene D; Sulaiman A; Sultan MA; Taha M; Tanaka J; Tarifi H; Tayyab G; Tolmane I; Ud Din M; Umar M; Valantinas J; Videčnik-Zorman J; Yaghi C; Yunihastuti E; Yusuf MA; Zuberi BF; Schmelzer JD
    J Viral Hepat; 2015 Dec; 22 Suppl 4():21-41. PubMed ID: 26513446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
    Mühlberger N; Schwarzer R; Lettmeier B; Sroczynski G; Zeuzem S; Siebert U
    BMC Public Health; 2009 Jan; 9():34. PubMed ID: 19161623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece.
    Savvas SP; Koskinas J; Sinani C; Hadziyannis A; Spanou F; Hadziyannis SJ
    J Viral Hepat; 2005 Sep; 12(5):551-7. PubMed ID: 16108773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and Elimination of HCV-Related Liver Disease.
    Pradat P; Virlogeux V; Trépo E
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30301201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
    Niederau C
    Med Klin (Munich); 2001 Oct; 96(10):599-607. PubMed ID: 11715332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study.
    Rao HY; Sun DG; Yang RF; Liu F; Wang J; Feng B; Wu N; Fang JL; Song GJ; Ma H; Guo F; Wang JH; Li XB; Jin Q; Qin H; Zhuang H; Wei L
    J Gastroenterol Hepatol; 2012 Mar; 27(3):526-32. PubMed ID: 21871021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of disease and cost of chronic hepatitis C infection in Canada.
    Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
    Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.